other
confidence high
sentiment neutral
materiality 0.60
NGM Biopharmaceuticals reprices underwater stock options for employees, effective after Q3 2023 filing
NGM BIOPHARMACEUTICALS INC
- Compensation Committee approved repricing of 7,037,470 eligible options with exercise prices >$5.00 to closing price on Effective Date.
- CEO David Woodhouse holds 2,449,846 options at original exercise prices $7.54-$31.93; options now deeply underwater (stock ~$1.02).
- Eligible options subject to 12-18 month retention period; early exercise requires original higher strike price.
- Outgoing President & CFO Siobhan Nolan Mangini's underwater options excluded from repricing; she departs Dec 1, 2023.
- Repricing covers 88% of eligible options with original exercise prices from $7.54 to $31.93 per share.